Literature DB >> 6767828

Amprolium for prophylaxis of ovine Sarcocystis.

R G Leek, R Fayer.   

Abstract

The efficacy of amprolium against clinical sarcocystosis resulting from Sarcocystis ovicanis was determined in two experiments involving 40 lambs. In each experiment, four lambs were used in each of five test groups--uninoculated unmedicated, inoculated unmedicated, uninoculated medicated (100 mg/kg), inoculated medicated (100 mg/kg), and inoculated medicated (50 mg/kg). Amprolium was provided as a feed additive to each medicated group for 31 days beginning 1 day before oral inoculation with 100,000 S. ovicanis sporocysts. Data from deaths, body temperatures, weight gains, serum protein levels, hematocrits, hemoglobin values, LDH and SGOT values, postmortem examinations, and histological examinations indicated that amprolium at both levels tested reduced the number of deaths and severity of clinical signs of sarcocystosis in experimentally infected lambs as compared with unmedicated controls.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6767828

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  4 in total

Review 1.  Human infections with Sarcocystis species.

Authors:  Ronald Fayer; Douglas H Esposito; Jitender P Dubey
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 2.  Sarcocystis spp. in human infections.

Authors:  Ronald Fayer
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

3.  Pathology of Sarcocystis campestris infection in Richardson's ground squirrels (Spermophilus richardsoni).

Authors:  G Wobeser; R J Cawthorn; A A Gajadhar
Journal:  Can J Comp Med       Date:  1983-04

4.  Lambs infected with UV-attenuated sporocysts of Sarcocystis ovicanis produced abnormal sarcocysts and induced protective immunity against a challenge infection.

Authors:  Abdel-Azeem Abdel-Baki; Gamal Allam; Thabet Sakran; El-Mahy El-Malah
Journal:  Korean J Parasitol       Date:  2009-05-27       Impact factor: 1.341

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.